Literature DB >> 12570014

New insights in insurmountable antagonism.

G Vauquelin1, I Van Liefde, B B Birzbier, P M L Vanderheyden.   

Abstract

Antagonists that produce parallel rightward shifts of agonist dose-response curves with no alteration of the maximal response are traditionally classified as surmountable, while insurmountable antagonists also depress the maximal response. Although the longevity of the antagonist-receptor complex is quoted in many studies to explain insurmountable antagonism, slowly interconverting receptor conformations, allosteric binding sites, and receptor internalization have been evoked as alternative explanations. To complicate matters even further, insurmountable antagonism is not only drug-related; it may also depend on the tissue, species and experimental design. For the sake of drug development, it is important to elucidate the molecular mechanisms of insurmountable antagonism. New experimental approaches, such as intact cell studies and the use of computer-assisted simulations based on dynamic receptor models, herald the advent of better insight in the future.

Mesh:

Substances:

Year:  2002        PMID: 12570014     DOI: 10.1046/j.1472-8206.2002.00095.x

Source DB:  PubMed          Journal:  Fundam Clin Pharmacol        ISSN: 0767-3981            Impact factor:   2.748


  13 in total

Review 1.  Elusive equilibrium: the challenge of interpreting receptor pharmacology using calcium assays.

Authors:  Steven J Charlton; Georges Vauquelin
Journal:  Br J Pharmacol       Date:  2010-11       Impact factor: 8.739

Review 2.  On the different experimental manifestations of two-state 'induced-fit' binding of drugs to their cellular targets.

Authors:  Georges Vauquelin; Isabelle Van Liefde; David C Swinney
Journal:  Br J Pharmacol       Date:  2016-03-15       Impact factor: 8.739

Review 3.  International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic Stimuli [corrected].

Authors:  Sadashiva S Karnik; Hamiyet Unal; Jacqueline R Kemp; Kalyan C Tirupula; Satoru Eguchi; Patrick M L Vanderheyden; Walter G Thomas
Journal:  Pharmacol Rev       Date:  2015-10       Impact factor: 25.468

4.  Phage display and hybridoma generation of antibodies to human CXCR2 yields antibodies with distinct mechanisms and epitopes.

Authors:  Christine J Rossant; Danielle Carroll; Ling Huang; John Elvin; Frances Neal; Edward Walker; Joris J Benschop; Eldar E Kim; Simon T Barry; Tristan J Vaughan
Journal:  MAbs       Date:  2014       Impact factor: 5.857

5.  Discovery of new antagonists aimed at discriminating UII and URP-mediated biological activities: insight into UII and URP receptor activation.

Authors:  D Chatenet; M Létourneau; Q T Nguyen; N D Doan; J Dupuis; A Fournier
Journal:  Br J Pharmacol       Date:  2013-02       Impact factor: 8.739

Review 6.  Clozapine, atypical antipsychotics, and the benefits of fast-off D2 dopamine receptor antagonism.

Authors:  Georges Vauquelin; Sophie Bostoen; Patrick Vanderheyden; Philip Seeman
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-02-14       Impact factor: 3.000

7.  Development of a potent DOTA-conjugated bombesin antagonist for targeting GRPr-positive tumours.

Authors:  Rosalba Mansi; Xuejuan Wang; Flavio Forrer; Beatrice Waser; Renzo Cescato; Keith Graham; Sandra Borkowski; Jean Claude Reubi; Helmut R Maecke
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-08-18       Impact factor: 9.236

8.  Isolation and pharmacological characterization of AdTx1, a natural peptide displaying specific insurmountable antagonism of the alpha1A-adrenoceptor.

Authors:  L Quinton; E Girard; A Maiga; M Rekik; P Lluel; G Masuyer; M Larregola; C Marquer; J Ciolek; T Magnin; R Wagner; J Molgó; R Thai; C Fruchart-Gaillard; G Mourier; J Chamot-Rooke; A Ménez; S Palea; D Servent; N Gilles
Journal:  Br J Pharmacol       Date:  2009-12-15       Impact factor: 8.739

9.  Pharmacokinetic-pharmacodynamic modeling of the antihypertensive effect of eprosartan in Black and White hypertensive patients.

Authors:  Petra C van Rijn-Bikker; Oliver Ackaert; Nelleke Snelder; Reinier M van Hest; Bart A Ploeger; Richard P Koopmans; Ron A A Mathôt
Journal:  Clin Pharmacokinet       Date:  2013-09       Impact factor: 6.447

10.  Application of linker technique to trap transiently interacting protein complexes for structural studies.

Authors:  Vishnu Priyanka Reddy Chichili; Veerendra Kumar; J Sivaraman
Journal:  J Biol Methods       Date:  2016
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.